Introgen seeks European orphan designation for Advexin
Li-Fraumeni syndrome (LFS) is a rare inherited genetic disorder that greatly increases the risk of developing several types of cancer typically with initial occurrence at a young age.
The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).